IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease
This study has been completed.
Sponsor:
VA Office of Research and Development
Information provided by (Responsible Party):
VA Office of Research and Development
ClinicalTrials.gov Identifier:
NCT00892450
First received: April 28, 2009
Last updated: October 2, 2014
Last verified: October 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this research study is to investigate the cognitive (thinking, memory, knowledge, intelligence) side effects of two medications commonly used to treat overactive bladder (OAB) symptoms in veteran patients with Parkinson's disease (PD) seen at the Philadelphia PADRECC.
| Condition | Intervention |
|---|---|
| Parkinson's Disease Overactive Bladder | Drug: Oxybutynin and darifenacin |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double Blind (Participant, Investigator) Primary Purpose: Treatment |
| Official Title: | Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease: A Randomized, Double-blind, Crossover Pilot Study |
Resource links provided by NLM:
Further study details as provided by VA Office of Research and Development:
Primary Outcome Measures:
- compare cognitive side effects [ Time Frame: 10 weeks ]
| Enrollment: | 12 |
| Study Start Date: | May 2009 |
| Study Completion Date: | September 2014 |
| Primary Completion Date: | September 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Arm 1
crossover design
|
Drug: Oxybutynin and darifenacin
Participants with overactive bladder will take each medication for 4 weeks.
|
Detailed Description:
This study will be a double-blinded cross-over clinical trial design to assess the prevalence of cognitive effects, the efficacy, and the effect on quality of life (QOL) of two anticholinergic medications commonly used in the treatment of overactive bladder (OAB): oxybutynin and darifenacin. This will be done by use of a well-established and validated computer-based cognitive battery. Secondary endpoints will assess efficacy of anticholinergic therapy on symptoms of OAB via QOL questionnaire and participant urinary diaries.
Eligibility| Ages Eligible for Study: | Child, Adult, Senior |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Diagnosis of idiopathic PD (ICD9=332.0)
- MMSE 24, able to give informed consent and complete questionnaires and voiding diaries.
-
Urological work-up within 3 months of enrollment to:
-
Rule out treatable causes of urinary symptoms
- Urinalysis (UA)
- Post-void residual ultrasound (PVR)
- Urinary cytology
-
Documented symptoms OAB on screening 3-day voiding diary:
- Average of 1 urgency episode / 24 hours, and
- Average of 8 micturitions / 24 hours
- Subjective complaints of symptoms for 3 months
-
Exclusion Criteria:
- Exposure to anticholinergics or antispasmodics within the last 4 weeks (among them: atropine, tolterodine, benztropine, trihexyphenidyl, dicyclomine, hyoscyamine, and scopolamine)
- Exposure to drugs with known effects on cognition (i.e. opioids, benzodiazepines or sedating antihistamines) within the last week
- Exposure to drugs contraindicated or cautioned in use with the 2 study medications (drugs that also use the cytochrome P450 enzyme, primarily CYP3A4). These include: ketoconazole, itraconazole, miconazole, erythromycin, clarithromycin, ritonavir, nelfinavir, nefazodone, flecainide, thioridazine and tricyclic antidepressants.
- Nonpharmacological treatment of OAB within the last 4 weeks (for example: biofeedback, physical therapy, acupuncture)
- Uncontrolled narrow angle glaucoma
- History of gastric or urinary retention / dysmotility (ulcerative colitis, myasthenia gravis and severe constipation)
- History of hepatic or renal impairment
- History of severe gastro-esophageal reflux disease and/or use of bisphosphonates, patients at risk for esophagitis
- Previous exposure to anticholinergic for OAB symptoms that resulted in side effects that caused cessation of the medication
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00892450
Please refer to this study by its ClinicalTrials.gov identifier: NCT00892450
Locations
| United States, Pennsylvania | |
| VA Medical Center, Philadelphia | |
| Philadelphia, Pennsylvania, United States, 19104 | |
Sponsors and Collaborators
VA Office of Research and Development
Investigators
| Principal Investigator: | Jayne R Wilkinson, MD | VA Medical Center, Philadelphia |
More Information
| Responsible Party: | VA Office of Research and Development |
| ClinicalTrials.gov Identifier: | NCT00892450 History of Changes |
| Other Study ID Numbers: |
01143 |
| Study First Received: | April 28, 2009 |
| Last Updated: | October 2, 2014 |
Keywords provided by VA Office of Research and Development:
|
Overactive bladder symptoms Parkinson's disease darifenacin oxybutynin cognition |
Additional relevant MeSH terms:
|
Parkinson Disease Urinary Bladder, Overactive Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders Neurodegenerative Diseases Urinary Bladder Diseases Urologic Diseases Lower Urinary Tract Symptoms Urological Manifestations |
Signs and Symptoms Darifenacin Oxybutynin Cholinergic Antagonists Muscarinic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Urological Agents Parasympatholytics Autonomic Agents Peripheral Nervous System Agents |
ClinicalTrials.gov processed this record on June 23, 2017